The DOI matches its Crossref record.
Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
Abstract
The synthetic matrix metalloproteinase inhibitor batimastat was tested for its ability to inhibit growth and metastatic spread of the B16‐BL6 murine melanoma in syngeneic C57BL/6N mice. Intraperitoneal administration of batimastat resulted in a significant inhibition in the number of lung colonies produced by B16‐BL6 cells injected i.v. The effect of batimastat on spontaneous metastases was examined in mice inoculated in the hind footpad with B16‐BL6 melanoma. The primary tumor was removed surgically after 26‐28 days. Batimastat was administered twice a day from day 14 to day 28 (pre‐surgery) or from day 26 to day 44 (post‐surgery). With both protocols, the median number of lung metastases was not significantly affected, but there was a significant reduction in the weight of the metastases. Finally, the effect of batimastat was examined on s.c. growth of B16‐BL6 melanoma. Batimastat administered daily, starting at day of tumor transplantation, resulted in a significant growth delay, whereas treatment starting at advanced stage tumor only reduced tumor growth marginally. Our results indicate that a matrix metalloproteinase inhibitor can not only prevent the colonization of secondary organs by B16‐BL6 cells but also limit the growth of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Changing views of the role of matrix metalloproteinases in metastasis
Chambers, A. F., & Matrisian, L. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.17.1260 · Cited by 1,588
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 842
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Matrix metalloproteinases in tumor invasion and metastasis
Stamenkovic, I. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0379 · Cited by 815
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis
John, A., & Tuszynski, G. (2001) · Pathology & Oncology Research · doi:10.1007/bf03032599 · Cited by 609
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Self-citationMatrix metalloproteinase inhibitors
Wojtowicz-Praga, S. M., Dickson, R. B., & Hawkins, M. J. (1997) · Investigational New Drugs · doi:10.1023/a:1005722729132 · Cited by 518
Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., Buckels, J. A. C., & for the Marimastat Pancreatic Cancer Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3447 · Cited by 438
Self-citationFlavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential
Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F. O., Natali, P. G., Brunetti, M., Aiello, F. B., & Piantelli, M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<595::aid-ijc21>3.0.co;2-5 · Cited by 437
MacDougall, J. R., & Matrisian, L. M. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690603 · Cited by 419
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
Schuler, G., & Steinman, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1183 · Cited by 416
Rasmussen, H. S., & McCann, P. P. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00023-5 · Cited by 413
Malignant ascites: Systematic review and guideline for treatment
Becker, G., Galandi, D., & Blum, H. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.018 · Cited by 349
Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
Turpeenniemi-Hujanen, T. (2005) · Biochimie · doi:10.1016/j.biochi.2005.01.014 · Cited by 289
Recent advances in matrix metalloproteinase inhibitor research
Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., & Whittaker, M. (1996) · Drug Discovery Today · doi:10.1016/1359-6446(96)89115-x · Cited by 281
Parsons, S. L., Watson, S. A., Brown, P. D., Collins, H. M., & Steele, R. J. C. (1997) · British Journal of Surgery · doi:10.1002/bjs.1800840206 · Cited by 229
Self-citationMarimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., Hawkins, R. E., McCulloch, P., Maughan, T., Brown, P. D., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600310 · Cited by 265
Self-citationThota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas · doi:10.1097/mpa.0000000000000753 · Cited by 12
Metadata
- Authors
- Chirvi, R. G. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D., & Giavazzi, R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-08
- Volume
- 58
- Issue
- 3
- Pages
- 460-464
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1986072849
- Cited by
- 219
- References
- 0
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.